Patents Assigned to Institute Pasteur
  • Immunoadjuvant flagellin-based compounds and use thereof
    Patent number: 9956284
    Abstract: The present invention relates to novel peptide compounds derived from flagellin originating from Salmonelle enterica that exhibit an in vivo immune adjuvant activity.
    Type: Grant
    Filed: October 7, 2016
    Date of Patent: May 1, 2018
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE, INSTITUT PASTEUR DE LILLE
    Inventor: Jean-Claude Sirard
  • Method, probe and kit for DNA in situ hybridization and use thereof
    Patent number: 9957555
    Abstract: The invention relates to a method for the detection of the occurrence of initiation of replication events in genomic DNA in a eukaryotic cell, involving contacting said eukaryotic cell comprising said genomic DNA with a first nucleotide probe, under conditions enabling in situ hybridization of said first nucleotide probe with a target region in the DNA genome, wherein said target region comprises a nucleic acid sequence which has no identified corresponding annealing RNA in a metabolically active cell and therefore remains RNA-free during transcription and replication of said DNA genome and detecting said first nucleotide probe hybridized to said DNA. Further detection of at least one RNA molecule can be achieved.
    Type: Grant
    Filed: March 16, 2012
    Date of Patent: May 1, 2018
    Assignees: INSTITUT PASTEUR, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: Laurent Arnaud Chatre, Miria Ricchetti
  • Methods of Treatment of inflammation related conditions using pluripotent anti-inflammatory and metabolic Modulators
    Publication number: 20180104202
    Abstract: Methods of treating acute and chronic inflammatory conditions, tissue transplant rejection, and/or organ transplant rejection comprising administering to a subject in need thereof a therapeutically effective amount of a pluripotent anti-inflammatory and metabolic modulators optionally in combination with one or more secondary therapeutic agents and pharmaceutical compositions thereof.
    Type: Application
    Filed: October 16, 2017
    Publication date: April 19, 2018
    Applicants: Institut Pasteur de Montevideo, Universidad de la República
    Inventors: Carlos Batthyány, Gloria Virginia López, Carlos Escande, Jorge Rodriguez Duarte, Williams Arturo Porcal Quinta, Rosina Dapueto Capuccio, Germán Adrian Galliussi López, María Pia Garat Nuñez, Marcelo Hill, Mercedes Segovia
  • Methods and pharmaceutical compositions for treating human immunodeficiency virus type 1 (HIV-1) infections
    Patent number: 9938528
    Abstract: The present invention provides methods and pharmaceutical compositions for treating human immunodeficiency virus type 1 (HIV-1) infections. In particular, the present invention relates to a method for treating HIV-1 infection in a subject in need thereof comprising administering the subject with a therapeutically effective amount of an inhibitor of SGT1 activity or expression.
    Type: Grant
    Filed: December 10, 2015
    Date of Patent: April 10, 2018
    Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), UNIVERSITE PARIS-SUD, INSTITUT GUSTAVE ROUSSY, UNIVERSITE PARIS DECARTES, UNIVERSITE PIERRE ET MARIE CURIE, INSTITUT PASTEUR, INSTITUTO NAZIONALE PER LE MALATTIE INFETTIE IRCCS LAZZARO SPALLANZANI, ASSISTANCE PUBLIQUE HOPITAUX DE PARIS (APHP)
    Inventors: Guido Kroemer, Jean-Luc Perfettini, Marie-Lise Gougeon, Awatef Allouch, Mauro Piacentini
  • 2-oxo-3,4-dihydropyridine-5-carboxylates and their use
    Patent number: 9932309
    Abstract: The present invention is directed to novel compounds of Formula (I), pharmaceutically acceptable salts or solvates thereof, and their use.
    Type: Grant
    Filed: July 28, 2015
    Date of Patent: April 3, 2018
    Assignees: Universite de Lille 2 Droit et Sante, Institut Pasteur de Lille, INSERM
    Inventors: Julie Charton, Benoit Deprez, Florence Leroux, Bart Staels, Anne Muhr-Tailleux, Nathalie Hennuyer, Sophie Lestavel, Sylvain Picon, Karen Aknin, Rajaa Boulahjar, Barbara Dubanchet
  • Methods and pharmaceutical compositions for the treatment of bacterial infections
    Patent number: 9919029
    Abstract: The present invention relates to methods and pharmaceutical compositions for the treatment of bacterial infections. In particular, the present invention relates to a Toll-like receptor (TLR) agonist for use in a method for the treatment of a bacterial infection in a subject in need thereof wherein the TLR agonist is administered to the subject in combination with at least one antibiotic.
    Type: Grant
    Filed: July 25, 2014
    Date of Patent: March 20, 2018
    Assignees: INSERM (Institut National de la Sante et de la Recherche Medicale), Universite de Droit et de la Sante de Lille 2, Centre National de la Recherche Scientifique (CNRS), Institut Pasteur de Lille, Universite de Lille 1 Sciences et Technologies, ETH Zurich, Universidad de la Republica
    Inventors: Wolf-Dietrich Hardt, Patrick Kaiser, Jean-Claude Sirard, Christophe Carnoy, Delphine Fougeron, Jose Alejandro Chabalgoity, Natalia Munoz
  • Recombinant measles viruses expressing epitopes of antigens of RNA viruses—use for the preparation of vaccine compositions
    Patent number: 9914937
    Abstract: The invention relates to a recombinant measles virus expressing a heterologous amino acid sequence derived from an antigen of a determined RNA virus, said recombinant measles virus being capable of eliciting a humoral and/or cellular immune response against measles virus or against said RNA virus or against both measles virus and against said RNA virus. It also relates to the use of said recombinant measles virus for the preparation of immunogenic composition.
    Type: Grant
    Filed: March 24, 2015
    Date of Patent: March 13, 2018
    Assignees: INSTITUT PASTEUR, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: Frederic Tangy, Clarisse Lorin, Lucile Mollet, Frederic Delebecque
  • Compound useful for the treatment of nonsense-mutation-mediated diseases and pharmaceutical composition comprising said compound
    Patent number: 9913829
    Abstract: The present invention relates to the compound of formula (I) for use in the treatment of a nonsense-mutation-mediated genetic disease.
    Type: Grant
    Filed: July 29, 2011
    Date of Patent: March 13, 2018
    Assignees: UNIVERSITE DE DROIT ET DE SANTE DE LILLE, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), INSTITUT PASTEUR DE LILLE
    Inventors: Fabrice Lejeune, Benoit Deprez, Terence Beghyn, Sara Sofia Gonzalez-Hilarion
  • Conjugated molecules comprising a peptide derived from the CD4 receptor coupled to an anionic polypeptide for the treatment of AIDS
    Patent number: 9907860
    Abstract: This invention relates to a conjugated molecule comprising a peptide derived from the CD4 receptor coupled to an organic molecule by means of a linker as well as a process for its preparation. Said organic molecule comprises a 5 to 21 amino acid anionic polypeptide. Such a conjugated molecule can be used in antiviral treatment, namely in the treatment of AIDS.
    Type: Grant
    Filed: October 23, 2015
    Date of Patent: March 6, 2018
    Assignees: INSTITUT PASTEUR, COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES, UNIVERSITE PARIS-SUD, UNIVERSITE GRENOBLE ALPES, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)
    Inventors: Francoise Baleux, Hugues Lortat-Jacob, David Bonnaffe, Yves-Marie Coic
  • Nitroalkene Trolox Derivatives and Methods of Use Thereof In The Treatment And Prevention of Inflammation Related Conditions
    Publication number: 20180057475
    Abstract: The present invention is directed to a class of anti-inflammatory, antioxidant nitroalkene compounds used in biological or biochemical applications to reduce oxidative stress or damage. The nitroalkene compounds described herein further avoid disadvantageous metabolism currently present in this field.
    Type: Application
    Filed: August 23, 2016
    Publication date: March 1, 2018
    Applicant: Institut Pasteur de Montevideo
    Inventors: Carlos Batthyány, Gloria Virginia López, Rosina Dapueto, Carlos Escande, Jorge Rodriguez Duarte
  • Transgenic immunodeficient mouse expressing human SIRP-alpha
    Patent number: 9894888
    Abstract: The present invention provides a transgenic mouse which comprises a deficiency for murine T lymphocytes, B lymphocytes and NK cells, a deficiency for murine MHC class I and MHC class II molecules, and a functional xenogenic SIRP? transgene. This mouse is useful for in vivo screening of various compounds, including immuno-therapeutic agents and vaccines. The said mouse is also useful for testing the in vivo metabolism of xenobiotic compounds.
    Type: Grant
    Filed: March 26, 2013
    Date of Patent: February 20, 2018
    Assignee: INSTITUT PASTEUR
    Inventors: Sylvie Garcia, Malika Serra-Hassoun
  • Use of a genetically modified infectious measles virus with enhanced pro-apoptotic properties (MV-deltaC virus) in cancer therapy
    Patent number: 9889193
    Abstract: The invention relates to a genetically modified infectious measles virus derived from a live-attenuated measles virus strain, in which the gene encoding the viral accessory C protein has been knocked out (MV-deltaC). It concerns in particular the use of said genetically modified infectious MV-deltaC in the treatment of malignant tumor or cancer conditions, and for the preparation of agents or compositions for such treatment.
    Type: Grant
    Filed: January 20, 2014
    Date of Patent: February 13, 2018
    Assignees: CENTRE NATIONAL DE LA RECHERCHE SCENTIFIQUE (CNRS), INSITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), INSTITUT PASTEUR, UNIVERSITE DE NANTES
    Inventors: Frédéric Tangy, Marc Gregoire, Jean-François Fonteneau, Jean-Baptiste Guillerme, Chantal Combredet
  • MULTIPLEX IMMUNO SCREENING ASSAY
    Publication number: 20180038852
    Abstract: The present invention provides kits and assay methods for the early detection of pathogens, precise identification of the etiologic agent, and improved disease surveillance. More specifically, the present invention discloses an immunoassay leading to the rapid and simultaneous detection of antibodies to a wide range of infectious pathogens in biological fluids of infected patients. This immunoassay involves the covalent and oriented coupling of fusion proteins comprising an AGT enzyme and a viral antigen on an identifiable solid support (e.g. fluorescent microspheres), said support being previously coated with an AGT substrate. This coupling is mediated by the irreversible reaction of the AGT enzyme on its substrate. The thus obtained antigen-coupled microspheres show enhanced capture of specific antibodies as compared to antigen-coupled microspheres produced by standard amine coupling procedures.
    Type: Application
    Filed: July 19, 2017
    Publication date: February 8, 2018
    Applicant: INSTITUT PASTEUR
    Inventors: Jean-Claude Manuguerra, Jessica Vanhomwegen, Philippe Despres, Sylvie Paulous
  • Rapid detection of the “high virulent” ST-17 clone of group B
    Patent number: 9874560
    Abstract: The present invention relates to polynucleotides enabling the rapid, simple and specific detection of Group B Streptococcus highly-virulent ST-17 clones. The present invention also relates to the polypeptides encoded by said polynucleotides, as well as to antibodies directed or raised against said polypeptides. The present invention also relates to kits and methods for the specific detection of Group B Streptococcus highly-virulent ST-17 clones, using the polynucleotides, the polypeptides or the antibodies according to the invention.
    Type: Grant
    Filed: October 12, 2016
    Date of Patent: January 23, 2018
    Assignees: INSTITUT PASTEUR, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE PARIS DESCARTES, ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
    Inventors: Claire Poyart, Marie-Cecile Lamy, Shaynoor Dramsi, Elisabeth Sauvage, Philippe Glaser, Patrick Trieu-Cuot
  • Mutation within the connexin 26 gene responsible for prelingual non-syndromic deafness and method of detection
    Patent number: 9868989
    Abstract: A purified polynucleotide having a chain of nucleotides corresponding to a mutated sequence, which in a wild form encodes a polypeptide implicated in hereditary sensory defect wherein said mutated purified polynucleotide presents a mutation responsible for prelingual non-syndromic deafness selected from the group consisting of a specific deletion of at least one nucleotide.
    Type: Grant
    Filed: September 18, 2015
    Date of Patent: January 16, 2018
    Assignee: INSTITUT PASTEUR
    Inventors: Christine Petit, Francoise Denoyelle-Gryson, Dominique Weil, Sandrine Marlin, Jean-Luc Guesdon
  • ADAM12 Inhibitors and Their Use Against Inflammation-Induced Fibrosis
    Publication number: 20170369888
    Abstract: The present invention relates to the field of fibrosis and inflammation and more particularly to the use of ADAM12 (A Disintegrin and Metalloproteinase 12) inhibitors to prevent or treat inflammation-induced fibrosis. The present invention also relates to the use of ADAM12 as a marker for inflammation-induced fibrosis and to the ablation of ADAM12 expressing cells as therapeutic approach to interfere with the development of pro-fibrotic cells.
    Type: Application
    Filed: August 29, 2017
    Publication date: December 28, 2017
    Applicant: Institut Pasteur
    Inventors: Lucie Peduto, Gerard Eberl
  • ANTIVIRAL AGENTS DIRECTED AGAINST RESPIRATORY SYNCYTIAL VIRUS
    Publication number: 20170360752
    Abstract: The present invention relates to N1-benzyl substituted pyrazoles as antiviral agents directed against respiratory syncytial virus.
    Type: Application
    Filed: November 5, 2015
    Publication date: December 21, 2017
    Applicants: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), INSTITUT NATIONAL DE LA RECHERCHEAGRONOMIQUE, Institut Pasteur, UNIVERSITÉ PARIS-SUD
    Inventors: Christina Sizun, Stéphane Duquerroy, Jean-François Eleouet, Felix Rey, Anny Slama Schwok, Didier Desmaele, Patrick Couvreur, Bogdan Tarus
  • Vaccine for prophylaxis or treatment of an allergen-driven airway pathology
    Patent number: 9839683
    Abstract: The present invention relates to a live attenuated Bordetella pertussis vaccine which is deficient for tracheal cytotoxin (TCT), pertussis toxin (PTX), and dermonecrotic toxin (DNT) for prophylaxis or treatment of an allergen-driven airway pathology.
    Type: Grant
    Filed: January 30, 2015
    Date of Patent: December 12, 2017
    Assignees: Institut National de la Sante et de la Recherche Medicale, Institut Pasteur de Lille, National University of Ireland Maynooth
    Inventors: Camille Locht, Bernard Mahon, Heather Kavanagh
  • Combinations of a caspase inhibitor and an antiviral agent
    Patent number: 9833492
    Abstract: A compound is provided which has a structure I: A-B-C and a method for administering the compound is also provided for use in the prophylaxis and/or treatment of a viral infection, and in particular for preventing and/or inhibiting viral replication, in which A is a quinoline or quinoline-like group, B is a sole amino acid or a peptide or polypeptide having a given amino acid sequence, and C is an O-phenoxy group. According to one embodiment, the compound is a protease inhibitor such as a caspase inhibitor, and the inhibitor can be Q-VD-OPh (N-(2-(quinolyl)valylaspartyl-(2,6-difluorophenoxyl)methyl ketone), optionally in an O-methylated form. Antiviral compositions and kits are also provided.
    Type: Grant
    Filed: May 15, 2015
    Date of Patent: December 5, 2017
    Assignees: Institut Pasteur, Institut National de la Santé et de la Recherche Médicale, Centre National de la Recherche Scientifique, Universite Paris—Sud
    Inventors: Jerome Estaquier, Mireille Laforge, Anna Senik
  • Multiplex Immuno Screening Assay
    Publication number: 20170336412
    Abstract: The present invention provides kits and assay methods for the early detection of pathogens, precise identification of the etiologic agent, and improved disease surveillance. More specifically, the present invention discloses an immunoassay leading to the rapid and simultaneous detection of antibodies to a wide range of infectious pathogens in biological fluids of infected patients. This immunoassay involves the covalent and oriented coupling of fusion proteins comprising an AGT enzyme and a viral antigen on an identifiable solid support (e.g. fluorescent microspheres), said support being previously coated with an AGT substrate. This coupling is mediated by the irreversible reaction of the AGT enzyme on its substrate. The thus obtained antigen-coupled microspheres show enhanced capture of specific antibodies as compared to antigen-coupled microspheres produced by standard amine coupling procedures.
    Type: Application
    Filed: July 19, 2017
    Publication date: November 23, 2017
    Applicant: Institut Pasteur
    Inventors: Jean-Claude MANUGUERRA, Jessica VANHOMWEGEN, Philippe DESPRES, Sylvie PAULOUS